PolyMedix, Inc.  

(Public, OTCMKTS:PYMXQ)   Watch this stock  
Find more results for PolyMedix Inc
-0.00009 (-90.00%)
Aug 27 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.00 - 0.00
52 week 0.00 - 0.00
Open 0.00
Vol / Avg. 1,460.00/4.00
Mkt cap 21.00
P/E     -
Div/yield     -
EPS -7.21
Shares 2.14M
Beta -2.13
Inst. own 0%

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -389.53% -652.02%
Operating margin -361.07% -781.32%
EBITD margin - -768.20%
Return on average assets - -112.80%
Return on average equity - -
Employees 28 -
CDP Score - -


Suite 300 170 N. Radnor Chester Road
RADNOR, PA 19087
United States - Map
+1-484-5982400 (Phone)
+1-484-5982401 (Fax)

Website links


PolyMedix, Inc. (PolyMedix) is a clinical-stage biotechnology company. PolyMedix is engaged in developing small-molecule drugs for the treatment of serious acute care conditions. The Company has created defensin mimetic antibiotic compounds, heparin antagonist compounds, and other drug compounds intended for human therapeutic. The Company has internally created a pipeline of infectious disease, cancer supportive care and cardiovascular product candidates. The Company’s product includes PMX-30063 and PMX-60056 and other PMX defensin-mimetics. In February 2011, the Company completed and announced positive results from a randomized, double-blind, placebo-controlled Phase I exposure-escalation clinical study where it evaluated the safety and pharmacokinetics of PMX-30063 in once-daily dosing up to 14 days.

Officers and directors

Shaun F. O'Malley Independent Chairman of the Board
Age: 76
Daniel Jorgensen M.D. Chief Medical Officer, Senior Vice President - Clinical Development
Bozena Korczak Ph.D. Vice President - Drug Development
Age: 59
Richard W. Scott Ph.D. Vice President - Research
Age: 58
Nicholas Landekic Director
Age: 53
Stefan D. Loren Ph.D. Independent Director
Age: 48
Douglas J. Swirsky Independent Director
Age: 44